The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Last week's pivotal trial success could give Celgene a second AML drug, setting up a battle against Roche's Venclexta and idasanutlin.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
As doubts grow about targeting the folate receptor, Immunogen’s decision to press on with mirvetuximab soravtansine looks desperate.
Jazz wants to expand its sleep portfolio, while Macrogenics hopes trial data will support its first new drug application.
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.